Home News Page 67

News

Oxford BioTherapeutics and Berlin Chemie Develop New Antibody-Drug Conjugate as Second Clinical Development Candidate...

Oxford BioTherapeutics, a biopharmaceutical company developing a range of innovative antibody-drug conjugates or ADCs based on the company's proprietary...

Catalent Pharma Solutions Inc. acquires Redwood Bioscience Inc

Leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, Catalent Pharma...

Glembatumumab Vedotin in Patients With Locally Advanced or Metastatic Breast Cancer

The glycoprotein NMB or gpNMB, a novel transmembrane protein which is overexpressed in 40% to 60% of breast cancers,...

What is the Potential of Antibody-based Therapies for Myeloma?

Optimal target antigen selection antibody-based therapeutics can be very effective agents for the treatment of hematologic malignancies. However, there...

Baxter BioPharma Solutions and SAFC Collaborate on Complete ADC Offering

Baxter’s BioPharma Solutions (BPS) business and Sigma-Aldrich Corporation’s SAFC® Custom Manufacturing Services business unit, have established a collaborative manufacturing...

Merck KGaA acquires Sigma-Aldrich

Merck KGaA (Darmstadt, Germany), the world’s oldest pharmaceutical and chemical company established in 1668 which operates as EMD Serono...

A Successful Liaison between Chemistry and Biology

The development of new therapies for the treatment of human diseases is arguably one of the most important roles...

Sutro Biopharma and Merck Partner in Developing of Antibody Drug Conjugates

Sutro Biopharma, a biopharmaceutical company developing antibody drug conjugates and bispecific antibodies, and the biopharmaceutical division of Merck KGaA,...

Study Results for KTN3379 Support Further Evaluation in Combinations with Targeted Therapies

Top-line results from a phase I open-label, dose escalation monotherapy trial of KTN3379 (Kolltan Pharmaceuticals, Inc), a human monoclonal...

Second Generation Antibody-drug Conjugates Requires New Technology

After the recent regulatory approval of two antibody-drug conjugates and the ongoing effort to identify more effective cytotoxic payloads...